小型非编码RNA:在阿尔茨海默病中开创了一个新的治疗时代
Sonali Sahoo1, Swagata Pattanaik1, Durga Madhab Kar1
1Department of Pharmacology, School of Pharmaceutical Sciences, Siksha 'O'Anusandhan Deemed to be University, Bhubaneswar, Odisha, India.
Gene
|October 17, 2025
概括
小型非编码RNA疗法通过向其遗传和分子根源,显示出对阿尔茨海默病 (AD) 治疗的前景. 克服血脑屏障仍然是这些创新的阿尔茨海默病治疗方法的关键挑战.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,有效治疗方法有限.
- 目前FDA批准的药物只能提供轻微的症状缓解,几乎没有疾病修饰的选择.
- 最近的发现凸显了非编码RNA在AD病变发生过程中的作用.
研究的目的:
- 审查AD病理生理学的最新发现,并确定新的治疗点.
- 探索开发基于小型非编码RNA的AD治疗方法.
- 讨论实施这些疗法的挑战和未来前景,包括克服血脑屏障.
主要方法:
- 关于AD病理生理学的最新研究的文献综述.
- 在AD中对小型非编码RNA类型 (miRNA,siRNA,piRNA,tsRNA) 的分析.
- 对通过血脑屏障传递小非编码RNA的策略的评估.
主要成果:
- 小型非编码RNA因其在阿尔茨海默病中的治疗潜力而越来越被认可.
- 了解AD的遗传和分子基础有助于开发向的RNA疗法.
- 通过血脑屏障进行输送是有效的基于RNA的治疗的关键障碍.
结论:
- 小型非编码RNA疗法代表了阿尔茨海默病治疗的前沿.
- 需要进一步的研究来应对治疗挑战和优化治疗策略.
- 这些方法提供了超越当前症状治疗的疾病修改潜力.
相关概念视频
siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K
Experimental RNAi
7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Small interfering RNAs (siRNA)
4.2K
4.2K
RNA Interference
27.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.8K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K


